个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Lim Young-Suk[1] * ; Chan Henry L Y[2] ; Ahn Sang Hoon[3] ; Seto Wai Kay[4] ; Ning Qin[5] ; Agarwal Kosh[6] ; Janssen Harry L A[7,8] ; Pan Calvin Q[9] ; Chuang Wan Long[10] ; Izumi Namiki[11] ; Fung Scott[12] ; Shalimar[13] ; Brunetto Maurizia[14] ; Hui Aric Josun[15] ; Chang Ting-Tsung[16] ; Lim Seng Gee[17] ; Abramov Frida[18] ; Flaherty John F[18] ; Wang Hongyuan[18] ; Yee Leland J[18] ; Kao Jia-Horng[19] ; Gane Edward[20] ; Hou Jinlin[21] ; Buti Maria[22,23] ;
单位： [1]Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. [2]The Chinese University of Hong Kong, Hong Kong. [3]Yonsei University College of Medicine, Seoul, Republic of Korea. [4]University of Hong Kong, Hong Kong. [5]Tongji Hospital, Tongji Medical College, Wuhan, China. [6]Institute of Liver Studies, Kings College Hospital, United Kingdom. [7]Toronto Western Hospital, Toronto, ON, Canada. [8]Division of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands. [9]NYU Langone Health, NYU Grossman School of Medicine, New York, NY, USA. [10]Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. [11]Musashino Red Cross Hospital, Tokyo, Japan. [12]Department of Medicine, University of Toronto, Toronto, Canada. [13]All India Institute of Medical Sciences, New Delhi, Delhi, India. [14]University Hospital of Pisa, Pisa, Italy. [15]Alice Ho Miu Ling Nethersole Hospital, Hong Kong. [16]National Cheng Kung University Medical College, Tainan, Taiwan. [17]National University Hospital, Singapore. [18]Gilead Sciences, Foster City, CA, USA. [19]National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. [20]Auckland Clinical Studies, Auckland, New Zealand. [21]Nanfang Hospital of Southern Medical University, Guangzhou, China. [22]Hospital Universitario Vall d'Hebron, Barcelona, Spain. [23]CIBEREHD del Instituto Carlos III., Barcelona, Spain.
出处：
DOI： 10.1016/j.jhepr.2023.100847

摘要：
Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in patients with CHB.The REACH-B, aMAP, and mPAGE-B models were utilized to assess HCC risk in patients with CHB from two global randomized-controlled trials evaluating the impact of TAF vs. TDF treatment. Standard incidence ratios (SIRs) were calculated using data from the REACH-B model as a ratio of observed HCC cases in the TAF- or TDF-treated patients vs. predicted HCC cases for untreated historical controls. Proportions of treated patients shifting aMAP and mPAGE-B risk categories between baseline and Week 240 were calculated.Of the 1,632 patients (TAF, n = 1,093; TDF, n = 539) followed for up to 300 weeks, 22 HCC cases developed. Those receiving TAF had an SIR that was lower compared to the SIR of individuals receiving TDF: 0.32 (p <0.001) vs. 0.56 (p = 0.06). In the general study population, individuals without cirrhosis at baseline had an SIR that was lower compared to the SIR of individuals with cirrhosis at baseline: 0.37 (p <0.001) vs. 0.58 (p = 0.15). Of the patients at low risk of HCC at baseline, the majority (97%) remained low risk by mPAGE-B and aMAP scoring at Week 240. Among those at medium or high risk at baseline, substantial portions shifted to a lower risk category by Week 240 (mPAGE-B: 22% and 42%; aMAP: 39% and 63%, respectively).This evaluation provides evidence that treatment with TAF or TDF can reduce HCC risk in patients with CHB, particularly in patients without cirrhosis.Despite the substantial impact of HCC on long-term outcomes of patients with CHB, the differential risk of HCC development among those receiving treatment with TAF vs. TDF has not been well elucidated. Using three validated risk prediction models, we found that TAF is at least as effective as TDF in reducing HCC risk in patients with CHB. While TDF is well-studied in the context of HCC risk reduction, our novel findings underscore the effectiveness of TAF as a treatment option for patients with CHB.NCT01940341; NCT02836249; NCT01940471; NCT02836236.© 2023 The Author(s).

基金：
This study was sponsored by Gilead Sciences. This article was based on the original studies GS-US-320-0108 and GS-US-320-0110 sponsored by Gilead Sciences. Support for third-party writing assistance for this article, provided by Julianna Catania, MPH, and Isabel Haber, BS, Costello Medical, US, was funded by Gilead in accordance with Good Publication Practice (GPP3) guidelines
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
最新[2025]版：
大类 | 1 区 医学
小类 | 2 区 胃肠肝病学
JCR分区：
出版当年[2021]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版：
Q1 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
通讯作者：
推荐引用方式(GB/T 7714)：
Lim Young-Suk,Chan Henry L Y,Ahn Sang Hoon,et al.Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B[J].JHEP REPORTS.2023,5(10):doi:10.1016/j.jhepr.2023.100847.
APA：
Lim Young-Suk,Chan Henry L Y,Ahn Sang Hoon,Seto Wai Kay,Ning Qin...&Buti Maria.(2023).Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B.JHEP REPORTS,5,(10)
MLA：
Lim Young-Suk,et al."Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B".JHEP REPORTS 5..10(2023)

资源点击量：428 今日访问量：0 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）